Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.50 |
| ▸ | SYK | P43405 | 2/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451814 | 0.84 | STS (0.50) | GPR119SYKSTSP2RY14HTT | |
| SCHEMBL6629645 | 0.83 | HTT (0.52) | GPR119HTTKDM4EMAPT | |
| SCHEMBL13807221 | 0.81 | STS (0.49) | GPR119STSP2RY14HTTKDM4E | |
| SCHEMBL25121090 | 0.78 | GPR119 (0.51) | GPR119KDM4EMAPTTHRB | |
| SCHEMBL25719736 | 0.78 | GPR119 (0.51) | GPR119KDM4EMAPTTHRB | |
| SCHEMBL13959341 | 0.78 | CCR2 (0.38) | — | |
| SCHEMBL13807225 | 0.77 | STS (0.48) | GPR119SYKSTSP2RY14HTT | |
| SCHEMBL24962316 | 0.77 | GPR119 (0.55) | GPR119STSP2RY14KDM4EMAPT | |
| SCHEMBL4451823 | 0.77 | GRM1 (0.49) | — | |
| SCHEMBL10324281 | 0.76 | GPR119 (0.49) | GPR119KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| WO-2007100610-A2 | PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | CXCR3, CXCR1, CXCR5 | GPR119 185/4885SYK 1052/4885STS 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.